Is the pharmaceutical supply chain changing dramatically? Is China's opportunity coming?

AI Question: How can China’s complete pharmaceutical industry chain enhance supply security?

Produced by | Miaodou APP

Author | Zhang Beibei

Editor | Ding Ping

Header Image | Visual China

The overlay of rare earth restrictions and logistics disruptions caused by US-Iran conflicts is gradually revealing overlooked issues within the global pharmaceutical supply chain.

For many years, many companies believed that as long as they minimized costs, kept inventories lean, and tightened delivery schedules, the supply chain was efficient; but now it’s clear that this model relies on a continuous supply of upstream raw materials and smooth international logistics. If either of these conditions fails, a seemingly smooth operation can quickly become fragile.

The most direct impacts are on key materials like rare earths and cross-border logistics. High-end equipment such as MRI and CT scanners, as well as cutting-edge nuclear medicines like Lu-177, depend heavily on critical raw materials; radioactive drugs, clinical samples, and precision components also rely on efficient transportation. When raw material supplies tighten or logistics are blocked, pharmaceutical companies face not just higher costs but also issues of timely production and delivery.

Especially if Middle Eastern logistics hubs fail, many problems will be amplified. Even with export permits, companies may struggle to ship goods smoothly; even if transportation resumes later, it doesn’t mean the supply chain will immediately return to normal, as high material prices, tight supplies, and extended delivery cycles may persist.

Therefore, this disruption is not just a short-term disturbance but a reminder that pharmaceutical supply chains must prioritize safety and controllability, not just efficiency.

This may trigger a new round of restructuring in the pharmaceutical supply chain. Those who can address gaps in key materials, manufacturing capacity, and supply stability are more likely to gain an advantage in the next phase. What role will China’s pharmaceutical industry play in this restructuring? Where will future development focus? And what transformation paths lie ahead? These are the questions worth exploring further.

Supply chains are no longer just about efficiency

For many years, the global pharmaceutical industry followed a simple logic: produce where costs are lowest and efficiency is highest. Raw materials, manufacturing, R&D, logistics—each segment was broken down into as many parts as possible, with costs pushed down as much as possible. When global trade was smooth, this model worked well.

But recent years have changed that. Geopolitical conflicts, trade frictions, and logistics disruptions have shown that the pharmaceutical industry cannot focus solely on efficiency; safety is equally important. The small savings during normal times can be far outweighed when supply is interrupted, shipments are halted, or supply chains break.

Now, the US, Europe, and Japan are all working on one thing: trying to bring critical drugs, raw materials, and manufacturing capabilities back within their own controllable domains.

The US aims to promote domestic production of some key active pharmaceutical ingredients (APIs), Europe is accelerating the construction of advanced therapy manufacturing bases, and Japan is subsidizing domestic production lines for sterile injectables and mRNA vaccines. Essentially, everyone is addressing the same weakness—where supply chains once prioritized “cheap and fast,” now the focus is on “stability and controllability.”

From this perspective, restrictions on rare earths or disruptions in Middle Eastern logistics are not isolated incidents. They simply expose a deeper issue: the previous cost-optimized approach to global pharmaceutical supply chains is increasingly insufficient.

In this wave of change, China may not just be a passive responder but could become even more important.

The reason is simple. China’s pharmaceutical industry is characterized not only by large capacity but also by a comprehensive supply chain.

From basic chemical raw materials, intermediates, APIs, to formulations, medical devices, packaging materials, and further to CRO/CDMO, distribution, and end markets—China has the capacity to supply at scale across these segments. While other countries may excel in certain areas, few can integrate so many segments into a cohesive system like China.

This capability’s value isn’t always obvious when the supply chain is stable, but as external environments become more volatile, its importance rises. Because ultimately, market competition is not just about which segment is strongest, but about who can keep the entire chain as stable as possible.

Take APIs as an example: China’s longstanding position isn’t just due to low costs but also because of comprehensive supporting infrastructure, full capacity, and quick response times. Even when raw material prices rise or logistics fluctuate externally, China’s vast chemical industry and diverse raw material sources often provide stronger buffers.

On the other hand, China’s innovation capacity is also improving. Historically viewed mainly as a manufacturing and contract processing hub, China’s R&D, licensing, and pipeline development are now significantly advancing. In short, China’s pharmaceutical industry is increasingly involved in upstream activities—deciding what drugs to develop, how to produce them, and where to sell.

Looking ahead, China’s role in the global pharmaceutical supply chain may shift from just a “cost center” or “manufacturing base” toward a more central position:

• Providing stable manufacturing and supply capabilities
• Gradually enhancing R&D, translation, and commercialization strengths

Those who can both supply reliably and innovate will naturally gain more influence.

Policy is also moving in this direction

If industry changes are driven by external pressures, policy shifts are proactive responses.

This year’s two sessions elevated biopharmaceuticals as a “new pillar industry,” signaling a clear message: pharmaceuticals are not just a livelihood industry but also a key driver of growth and competitiveness.

This repositioning is crucial. Once placed in the “pillar industry” category, the support will extend beyond rhetoric to include resources, policies, capital, and talent. In other words, the government’s expectations for the pharmaceutical sector are no longer just “supply security” but also “upgrading,” “breakthroughs,” and “enhanced international competitiveness.”

Focusing on the supply chain, the most critical areas are: innovative drugs and APIs.

One represents upward technological advancement; the other provides foundational stability.

(1) Innovative Drugs: Not just about sales

Policy support for innovative drugs has become increasingly comprehensive.

On the regulatory side, efforts are underway to streamline access, such as adjusting hospital drug evaluation and insurance cost controls; on the reimbursement side, new space is opening for innovative drugs, with commercial insurance and multi-layered payment systems responding to the market’s core concern: can the drug be profitable?

Previously, many companies focused on entering the insurance reimbursement list, as without it, sales couldn’t grow significantly. But the logic is shifting. Insurance is now seen as the baseline, while truly clinically valuable and differentiated innovative drugs will rely more on commercial insurance, self-pay, and multi-tiered payment systems to achieve higher returns.

This will directly influence R&D strategies.

In the future, success will no longer be about making “just insurance-eligible” drugs but about developing truly effective, differentiated products that payers are willing to invest in. This change is positive for the industry, as it shifts competition from low-level repetition to genuine innovation.

Additionally, “AI +” in medicine—particularly AI-driven drug discovery—is gaining attention. This isn’t just a buzzword; it offers real potential to shorten R&D cycles and reduce trial-and-error costs. For China, with its data, computing power, and engineering capabilities, integrating AI with drug R&D could push the innovation frontier further.

Thus, innovative drugs are not just a high-growth segment but also a catalyst for industry advancement. Once successful, they will boost upstream research tools, reagents, equipment, and R&D platforms.

(2) APIs: Not just “low-cost manufacturing”

The other key area is APIs.

In the past, APIs were often seen as “low-margin, high-volume” commodities—produced mainly through cost-driven, scale-intensive, environmentally regulated processes. But in today’s environment of repeated global supply chain disruptions, the importance of APIs is being re-recognized.

APIs are the foundation of the entire pharmaceutical industry.

Without them, both generic and innovative drugs cannot be developed or produced. Those who control stable, scalable, and reliable API supplies will have a stronger, irreplaceable position in the industry.

China’s advantages in this area are hard to fully replace in the short term.

It’s not just because of large output but also because many categories have established complete supporting systems and scale advantages. While Western countries have been advocating localization and reducing dependence, relocating these capacities back faces real issues—cost, time, environmental standards, talent, and supporting infrastructure. It’s not a matter of simply wanting to move.

More importantly, China is no longer just producing low-end bulk APIs. It has gained a stronger foothold in high-end specialty APIs, patent drug intermediates, and advanced contract manufacturing (CDMO) services. This shift indicates that the industry’s advantage is moving from “large volume and low price” toward “both volume and quality.”

Note: “Patent drug support” mainly refers to contract manufacturing services providing APIs and intermediates for original drug developers, including simple CMO services and more advanced process R&D and technical innovation (D) capabilities, aimed at optimizing processes, reducing costs, and solving technical challenges.

Therefore, the API segment should not be viewed merely as maintaining the status quo. It is the foundation for China’s continued upward movement in the pharmaceutical industry. A more stable base means broader development prospects for the entire pharmaceutical sector—from R&D to manufacturing.

In conclusion

The current changes in the pharmaceutical industry are not simply summarized as “resilience era,” but more directly as:

In the past, global pharma competed mainly on who was cheaper and faster; in the future, it will increasingly compete on who is more stable, comprehensive, and capable of continuous innovation.

Within this framework, China has the opportunity to reposition itself.

On one hand, a complete industry chain enhances China’s role in “supply security”; on the other, advancing innovation capabilities allows China to move beyond order-taking and manufacturing, toward higher value-added participation.

The current policy focus on innovative drugs and APIs aligns with this strategy: one aims to break through upward, the other to solidify the foundation. If both can be established, China’s role in the global supply chain restructuring will not be just “following changes,” but actively leading the way.